I missed this article when it came out almost a year ago.  The “Yamanaka factors” (abbreviated OSKM) are four chemicals which, when applied together, can turn an ordinary differentiated cell (a skin cell, for example) back into the stem cell from which it came.  Pluripotent stem cells replenish all the cell needs in the body.  The offspring of a stem cell can be any kind of cell, hence “pluripotent”.  Up until ten years ago, it was thought that this was a one-way street, and that the process of differentiation was irreversible.  Then the Kyoto laboratory of Shinya Yamanaka reported success in “de-differentiating” cells by adding just four chemicals, initials O, S, K and M.  In other words, these four chemicals turn a regular skin or muscle or organ cell back into the stem cell from whence it came.

I am guessing Alan, that Florentine is very young, and 70 is sufficiently abstracted not to mean anything.

Bachem announced today that Dr. Lester Mills will become the fourth member of the company’s Corporate Executive Committee on 1 January 2009. Lester Mills will be responsible for global marketing and sales, and will strengthen the existing team of Rolf Nyfeler, chief executive officer, Daniel Er

Hi Mark, Putting Tellorite aside. As regards biotech start up companies as a generic group. Does you agree that purpose of company is to sell stock based of the scam that they will have a great drug.

Very interesting, thanks for that – I was not aware of that blog, or of the connection between AMPK and telomeres via TERRA.

Mouse NK cells were isolated by negative immunomagnetic selection (Stem cell Technologies). The cells were cultured in a 5% CO2 incubator at 37°C in culture media containing 5000 IU/ml IL-2 for 10 d. The culture medium used was RPMI-1640 supplemented with 10% FBS, 0.25 μg/ml amphotericin B, 10 U/ml penicillin G, 100 μg/ml streptomycin, 1 mM L-glutamine, 1% nonessential amino acids (Invitrogen), and 50 μM 2-mercaptoethanol. Purity of NK cells was determined by FACS analysis. The murine melanoma B16F10 and lymphoma EL4 and YAC-1 cells were purchased from ATCC (Manassas, VA).

My health insurance is rarely used because it will not pay for the type of testing I want independent of an obvious disorder or disease.

Depending on which press report one reads, the presence of contaminant was either discovered by the manufacturer during process optimization, or by Novartis’ generic drugs subsidiary Sandoz, during routine raw material testing (13). 

Guy Nehemya, our Chief Operating Officer, has served in such capacity since March 2017. Mr. Nehemya joined the Company in October 2013 as the Company’s Director of Operations, after completing his internship at Agmon, Rosenberg, HaCohen & Co. Law Offices. Mr. Nehemya was a key member of management during the Company’s initial public offering and execution thereof. Mr. Nehemya holds a LL.B. from the College of Management and is currently completing his MBA degree at the IDC Herzliya. Mr. Nehemya has been a member of the Israeli Bar Association since 2012.

Cellmid Limited ( ASX:CDY.AX ) is an Australian biotechnology company developing innovative new therapies and diagnostic tests for heart attack, inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. Midkine is a cytokine that promotes cell migration, growth and survival. Discovered over twenty years ago, midkine’s roles in inflammation and cell survival have been extensively validated by researchers worldwide. Elevated midkine concentration in the blood or other body fluids is strongly indicative of cancer. Cellmid’s first product is a blood test that sensitively and accurately measures serum midkine levels. As well as developing this test in-house, Cellmid is actively out-licensing its broad diagnostic patent portfolio for the early detection, monitoring, prognosis and disease monitoring of cancer. The Company’s most advanced clinical development program targets the treatment of heart attack (acute myocardial infarction or AMI) utilising the midkine protein and its anti-apoptotic characteristics. Cellmid is also humanising its lead anti-midkine antibody for the treatment of inflammatory and autoimmune disorders.

The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for Aramchol or any future product candidates will be granted on a timely basis, if at all.

        Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted regulatory approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Such restrictions under applicable federal and state healthcare laws and regulations, include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price reporting and physician sunshine laws. Some of our pre-commercial activities are subject to some of these laws.